Resveratrol prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy and improves glucose and lipid profile of diabetic dam

Molecular Nutrition and Food Research

Volumn 55, Issue 8, 2011, Pages 1186-1196

  Singh, Chandra K ^a   Kumar, Ambrish ^a   Hitchcock, David B ^b   Fan, Daping ^a   Goodwin, Richard ^a   Lavoie, Holly A ^a   Nagarkatti, Prakash ^a   Dipette, Donald J ^a   Singh, Ugra S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; Diabetic embryopathy; Oxidative stress; Resveratrol

Indexed keywords

CASPASE; GLUTATHIONE; LIPID; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; BLOOD; DRUG EFFECT; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; FEMALE; FETUS DISEASE; GLUCOSE BLOOD LEVEL; LIPID PEROXIDATION; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PREGNANCY; PREGNANCY DIABETES MELLITUS; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CASPASES; EMBRYONIC DEVELOPMENT; ENZYME ACTIVATION; FEMALE; FETAL DISEASES; GLUTATHIONE; LIPID PEROXIDATION; LIPIDS; MALE; OXIDATIVE STRESS; PREGNANCY; PREGNANCY IN DIABETICS; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

RODENTIA; VITACEAE;

EID: 79961060269     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000457     Document Type: Article

References (45)

1. Rosenn, B., Miodovnik, M., Combs, C. A., Khoury, J., Siddiqi, T. A., Glycemic thresholds for spontaneous abortion and congenital malformations in insulin-dependent diabetes mellitus. Obstet. Gynecol. 1994, 84, 515-520.
2. Wilson, G. N., Howe, M., Stover, J. M., Delayed developmental sequences in rodent diabetic embryopathy. Pediatr. Res. 1985, 19, 1337-1340.
3. Miller, E., Hare, J. W., Cloherty, J. P., Dunn, P. J. et al., Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N. Engl. J. Med. 1981, 304, 1331-1334.
4. Suhonen, L., Hiilesmaa, V., Teramo, K., Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 2000, 43, 79-82.
5. Casson, I. F., Clarke, C. A., Howard, C. V., McKendrick, O. et al., Outcomes of pregnancy in insulin dependent diabetic women: results of a five-year population cohort study. Br. Med. J. 1997, 315, 275-278.
6. Galindo, A., Burguillo, A. G., Azriel, S., Fuente Pde, L., Outcome of fetuses in women with pregestational diabetes mellitus. J. Perinat. Med. 2006, 34, 323-331.
7. Becerra, J. E., Khoury, M. J., Cordero, J. F., Erickson, J. D., Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 1990, 85, 1-9.
8. Ornoy, A., Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy. Reprod. Toxicol. 2007, 24, 31-41.
9. Chappell, J. H., Jr., Wang, X. D., Loeken, M. R., Diabetes and apoptosis: neural crest cells and neural tube. Apoptosis 2009, 14, 1472-1483.
10. Reece, E. A., Wu, Y. K., Zhao, Z., Dhanasekaran, D., Dietary vitamin and lipid therapy rescues aberrant signaling and apoptosis and prevents hyperglycemia-induced diabetic embryopathy in rats. Am. J. Obstet. Gynecol. 2006, 194, 580-585.
11. Sugimura, Y., Murase, T., Oyama, K., Uchida, A. et al., Prevention of neural tube defects by loss of function of inducible nitric oxide synthase in fetuses of a mouse model of streptozotocin-induced diabetes. Diabetologia 2009, 52, 962-971.
12. Freinkel, N., Diabetic embryopathy and fuel-mediated organ teratogenesis: lessons from animal models. Horm. Metab. Res. 1988, 20, 463-475.
13. Evers, I. M., de Valk, H. W., Visser, G. H., Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. Br. Med. J. 2004, 328, 915.
14. Mills, J. L., Signore, C., Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res. A Clin. Mol. Teratol. 2004, 70, 844-845.
15. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L. et al., Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8, 157-168.
16. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H. et al., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127, 1109-1122.
17. Lekli, I., Szabo, G., Juhasz, B., Das, S. et al., Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H859-H866.
18. Virgili, M., Contestabile, A., Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci. Lett. 2000, 281, 123-126.
19. Guleria, R. S., Pan, J., Dipette, D., Singh, U. S., Hyperglycemia inhibits retinoic acid-induced activation of Rac1, prevents differentiation of cortical neurons, and causes oxidative stress in a rat model of diabetic pregnancy. Diabetes 2006, 55, 3326-3334.
20. Hu, M. L., Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994, 233, 380-385.
21. Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351-358.
22. Zabihi, S., Wentzel, P., Eriksson, U. J., Altered uterine perfusion is involved in fetal outcome of diabetic rats. Placenta 2008, 29, 413-421.
23. Wentzel, P., Gareskog, M., Eriksson, U. J., Folic acid supplementation diminishes diabetes- and glucose-induced dysmorphogenesis in rat embryos in vivo and in vitro. Diabetes 2005, 54, 546-553.
24. Brill, A., Torchinsky, A., Carp, H., Toder, V., The role of apoptosis in normal and abnormal embryonic development. J. Assist. Reprod. Genet. 1999, 16, 512-519.
25. Sun, F., Kawasaki, E., Akazawa, S., Hishikawa, Y. et al., Apoptosis and its pathway in early post-implantation embryos of diabetic rats. Diabetes Res. Clin. Pract. 2005, 67, 110-118.
26. Zhao, Z., Yang, P., Eckert, R. L., Reece, E. A., Caspase-8: a key role in the pathogenesis of diabetic embryopathy. Birth Defects Res. B Dev. Reprod. Toxicol. 2009, 86, 72-77.
27. Kruman, I., Bruce-Keller, A. J., Bredesen, D., Waeg, G., Mattson, M. P., Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 1997, 17, 5089-5100.
28. Ong, W. Y., Lu, X. R., Hu, C. Y., Halliwell, B., Distribution of hydroxynonenal-modified proteins in the kainate-lesioned rat hippocampus: evidence that hydroxynonenal formation precedes neuronal cell death. Free Radic. Biol. Med. 2000, 28, 1214-1221.
29. Chi, T. C., Chen, W. P., Chi, T. L., Kuo, T. F. et al., Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci. 2007, 80, 1713-1720.
30. Lindegaard, M. L., Damm, P., Mathiesen, E. R., Nielsen, L. B., Placental triglyceride accumulation in maternal type 1 diabetes is associated with increased lipase gene expression. J. Lipid Res. 2006, 47, 2581-2588.
31. Rivera, L., Moron, R., Zarzuelo, A., Galisteo, M., Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77, 1053-1063.
32. Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G. et al., Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91, 1590-1597.
33. Pervaiz, S., Holme, A. L., Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal. 2009, 11, 2851-2897.
34. Elliott, P. J., Walpole, S., Morelli, L., Lambert, P. D. et al., Resveratrol/SRT-501. Drugs Fut. 2009, 34, 291.
35. Palsamy, P., Subramanian, S., Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed. Pharmacother. 2008, 62, 598-605.
36. Wenzel, E., Soldo, T., Erbersdobler, H., Somoza, V., Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 2005, 49, 482-494.
37. Gareskog, M., Cederberg, J., Eriksson, U. J., Wentzel, P., Maternal diabetes in vivo and high glucose concentration in vitro increases apoptosis in rat embryos. Reprod. Toxicol. 2007, 23, 63-74.
38. Penumathsa, S. V., Thirunavukkarasu, M., Zhan, L., Maulik, G. et al., Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell Mol. Med. 2008, 12, 2350-2361.
39. Schein, P. S., Loftus, S., Streptozotocin: depression of mouse liver pyridine nucleotides. Cancer Res. 1968, 28, 1501-1506.
40. Gupta, S., Arora, S., Trivedi, S. S., Singh, R., Dyslipidemia in pregnancy may contribute to increased risk of neural tube defects - a pilot study in north Indian population. Ind. J. Clin. Biochem. 2009, 24, 150-154.
41. Cho, I. J., Ahn, J. Y., Kim, S., Choi, M. S., Ha, T. Y., Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 2008, 367, 190-194.
42. Kazmin, A., Garcia-Bournissen, F., Koren, G., Risks of statin use during pregnancy: a systematic review. J. Obstet. Gynaecol. Can. 2007, 29, 906-908.
43. Salbaum, J. M., Kappen, C., Neural tube defect genes and maternal diabetes during pregnancy. Birth Defects Res. A Clin. Mol. Teratol. 2010, 88, 601-611.
44. Ates, O., Cayli, S. R., Yucel, N., Altinoz, E. et al., Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J. Clin. Neurosci. 2007, 14, 256-260.
45. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C., Beaudeux, J. L., Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7-16.